Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775679 | 0.88 | GAA (0.49) | GAAKDM4EPOLBSMN1; SMN2HTT | |
| SCHEMBL6588104 | 0.87 | KDM4E (0.56) | GAAKDM4EPOLBSMN1; SMN2HTT | |
| SCHEMBL11255716 | 0.87 | GAA (0.49) | GAAKDM4ESMN1; SMN2HTTALDH1A1 | |
| SCHEMBL23137996 | 0.83 | GAA (0.52) | GAAKDM4EPOLBSMN1; SMN2HTT | |
| SCHEMBL12082180 | 0.83 | GAA (0.49) | GAAKDM4EPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4728790 | 0.81 | GAA (0.48) | GAAKDM4EPOLBSMN1; SMN2HTT | |
| SCHEMBL27808161 | 0.80 | GAA (0.57) | GAAKDM4EPOLBSMN1; SMN2HTT | |
| SCHEMBL8576931 | 0.77 | CA1 (0.50) | — | |
| SCHEMBL8900419 | 0.76 | GAA (0.72) | GAAKDM4EPOLBSMN1; SMN2HTT | |
| SCHEMBL2476221 | 0.76 | GAA (0.62) | GAAKDM4EPOLBSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154979-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | PFIZER LTD (GB) | 2018-03-07 | — | — | EP | disclosed |
| US-9802945-B2 | Imidazopyridazine derivatives as modulators of the GABAA receptor activity | PFIZER LIMITED (GB) | 2017-10-31 | — | — | US | disclosed |
| US-20170197965-A1 | Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity | PFIZER LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| EP-3154979-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | Pfizer Limited (GB) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189744-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | PFIZER LIMITED (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197965-A1 | Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity | GABRA5, GABRA3, GABRA2 | GAA 4020/4885KDM4E 2315/4885POLB 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.